Cerecor (CERC) Receiving Somewhat Positive Media Coverage, Report Shows
Media headlines about Cerecor (NASDAQ:CERC) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerecor earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5387456967354 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of research firms recently weighed in on CERC. ValuEngine raised shares of Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th. TheStreet raised shares of Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.
Cerecor (NASDAQ CERC) opened at $3.03 on Monday. Cerecor has a 1 year low of $0.34 and a 1 year high of $3.73. The company has a market cap of $88.27 and a P/E ratio of 8.19.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.